



## **X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta® (axitinib) in Patients with Clear Cell Renal Cell Carcinoma**

May 16, 2018

*Study designed to evaluate X4P-001-IO in combination therapy to be presented at the Annual Meeting of the Association Society of Clinical Oncology*

**Cambridge, MA – May 16, 2018** – [X4 Pharmaceuticals](#), a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting [X4P-001-IO](#), the company's CXCR4 antagonist, has been selected for poster presentation at the 2018 Association Society of Clinical Oncology (ASCO) annual meeting, taking place June 1-5 in Chicago. The presentation will describe clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).

Details of the presentation on X4P-001 are as follows:

**Title:**

A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma

**Authors:**

Ulka Vaishampayan, M.D., Barbara Ann Karmanos Cancer Institute, Detroit, MI  
Michael Atkins, M.D., Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC

**Abstract #:** 4510

**Poster Session:** Genitourinary (Nonprostate) Cancer

**Session Type:**

Poster Discussion Session, chosen as a select poster where expert discussants will highlight the most clinically applicable and novel posters, with abstract authors participating as panel members

**Date and Time:** June 2, 2018, 1:15 PM-2:30 p.m. CT

**About X4P-001-IO in Cancer**

[X4P-001-IO](#) is an investigational selective, oral, small molecule antagonist of C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in abundance on certain immune cells and cancer cells and it plays a critical role in immune cell trafficking, infiltration and activation in the tumor microenvironment. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO has the ability to help restore immunity within the tumor microenvironment and has the potential to enhance the anti-tumor activity of approved and emerging oncology agents, such as checkpoint inhibitors and targeted therapies. X4P-001-IO is being investigated in several clinical studies in solid tumors.

**About X4 Pharmaceuticals**

[X4 Pharmaceuticals](#) is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. The Company's oral small molecule drug candidates antagonize the [CXCR4](#) pathway, which plays a central role in immune surveillance. X4's most advanced product candidate, X4P-001-RD, is in a Phase 2/3 study in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease. X4P-001-IO is currently under investigation in multiple clinical studies in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit [x4.theyatesnetwork.com](http://x4.theyatesnetwork.com).

Inlyta® is a registered trademark of Pfizer.

**Media Contact:**

Kathryn Morris  
Tel: 914-204-6412  
[kathryn@theyatesnetwork.com](mailto:kathryn@theyatesnetwork.com)